BioCatalystWatch
ATAIWorkspace / ATAI / OverviewCompany library
Price
Market cap
Next catalystExpected Q4 2026VLS-01 · Phase 2 dataSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

BPL-003

5-HT1A / 5-HT2A

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

BPL-003

5-HT1A / 5-HT2A

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved
VLS-01

5-HT1 receptors / 5-HT2 receptors / 5-HT6 receptors / 5-HT7 receptors

PreINDP1P2P3FilingApproved
Next
PreINDP1P2P3FilingApproved

Waiting clinical

PreINDP1P2P3FilingApproved
DMX-1002

PreINDP1P2P3FilingApproved
EMP-01

PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
GRX-917

TSPO

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved
INB-01

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

Historical archive

Mu-opioid receptor (MOR)

PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing


PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

ATAI SEC archive